论文信息 - Immune Checkpoint Inhibitor-Associated Myositis. - 字舞流文

Immune Checkpoint Inhibitor-Associated Myositis.

August 14, 2018 743

A. Mammen | Douglas B. Johnson | W. Stenzel | J. Moslehi | S. Léonard-Louis | J. Salem | Y. Allenbach | O. Benveniste | C. Anquetil | B. Lebrun-Vignes | S. Leonard-Louis

[1] Bénédicte Lebrun-Vignes,et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis , 2018, The Lancet.

[2] G. C. Dobloug,et al. Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study , 2017, Annals of the rheumatic diseases.

[3] S. Živković,et al. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review , 2017, Neuromuscular Disorders.

[4] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[5] T. Barnetche,et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis , 2015, BMC Medicine.